-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
New York, November 12, 2021/PRNewswire/ ---Treadwell Therapeutics ("Treadwell Therapeutics") is a clinical-stage biotechnology company that develops new drugs for highly aggressive cancers.
The 36th was held today at the Washington Convention Center in Washington, D.
C.
and online.
A poster about the company's CFI-402411 clinical project was released at the Annual Meeting of the Society for Cancer Immunotherapy (SITC) (November 10-14, 2021)
.
Hematopoietic progenitor kinase 1 (HPK1) has a negative regulatory effect on immune cell activation, and CFI-402411 is the first oral inhibitor of its kind against HPK1
Dr.
Omid Hamid, Director of Research/Immuno-oncology at the Angeles Clinic and Research Institute affiliated to Cedarsene, Los Angeles, California, said: “CFI-402411 is a potent oral HPK1 (hematopoietic progenitor kinase 1, also known as mitogen activated protein).
Kinase 1, MAP4K1) small molecule inhibitor.
HPK1 is a negative regulator of T cell and B cell response
.
We have seen the initial tolerability and clinical benefits of this inhibitor in patients with multiple solid tumors, including PD1 Treat the patient
Dr.
Michael Tusche, co-CEO of Treadwell Therapeutics, said: “Using CFI-402411 to inhibit HPK1 is a new method of stimulating anti-tumor immunity through oral therapy
2021 SITC poster display and detailed information:
TWT-101: CFI-402411 (hematopoietic progenitor kinase-1 (HPK1) inhibitor) monotherapy and combination with pembrolizumab in the treatment of subjects with advanced solid malignancies, the first phase 1/2 study in humans
Publication number: 489
Poster showroom
Time: November 12, 2021, 7:00-8:30 am
In the title "TWT-101: CFI-402411 (hematopoietic progenitor kinase-1 (HPK1) inhibitor) monotherapy and combination with pembrolizumab in the treatment of subjects with advanced solid malignancies, the first phase 1/2 study in humans "In the presentation report, the exploratory in vitro SLP-76 test showed that CFI-402411 showed tolerable safety, linear pharmacokinetics, and biological safety in patients up to a dose of 400 mg (dose once a day).
Effective concentration, in this group of unselected patients (N=16) who have undergone extensive treatment, 5 patients have reached stable condition during at least one tumor assessment, and 2 patients (salivary gland and basal cell carcinoma) have at least 3 tumors Stable condition was reached during the assessment
.
Patients with basal cell carcinoma have previously received anti-PD1 antibody treatment
About CFI-402411
CFI-402411 is a highly effective HPK1 inhibitor.
It has been shown in preclinical studies to have immune priming effects, including reducing the inhibition of T cell receptors (TCR), destroying the expression of abnormal cytokines, and passing effector cells (ie, regulating Sex T cells or Treg) change the tumor immunosuppressive environment, and have a powerful anti-leukemia effect in several mouse models
.
About TWT-101
TWT-101 is a phase 1/2 clinical trial that uses CFI-402411 for advanced solid malignant tumors
.
The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CFI-402411, and to determine the optimal dose as a single-agent therapy and in combination with the anti-PD1 antibody pembrolizumab
About Treadwell Therapeutics
TD Biosciences is a science-driven biotechnology company that covers multiple molecular species at the clinical stage and originated from the University Health Network (UHN) of Toronto
.
TD Biotech focuses on developing the world's first and best-in-class tumor drugs to help cancer patients.
